PubMed Health⌕ Search

PubMed · 10204272

[Anticonvulsive therapy in eclampsia--its current status].

Abstract

Conflicting opinions on the adequate and appropriate anticonvulsive therapy for eclampsia stems from the fact that a lot of unclarity still exists as per the reasons for eclamptic seizures. The authors reviews current data from literature on the problem of anticonvulsive therapy for eclampsia and tries to clarify the uncertainties on the optimal approach for eclamptic seizures. Despite the fact that many neurologists in the U.S. as well as a great number of obstetricians in Europe are now sceptical about the anticonvulsive effect of magnesium sulphate and prefer other anticonvulsive agents, the parenteral application of magnesium is still the principal approach for eclampsia. There is a need however for a new strategy for prophylaxis and therapy of eclampsia. Which will lead to a significant reduction of the fatality rate in cases of grave preeclampsia-eclampsia.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Bozhinova. 1998. [Anticonvulsive therapy in eclampsia--its current status].. https://pubmed.ncbi.nlm.nih.gov/10204272/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗